MAIA Biotechnology (MAIA) Stock Price, News & Analysis

Company Overview

MAIA Biotechnology, Inc. is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods. In parallel, MAIA Biotechnology is advancing therapeutic constructs that couple monoclonal antibodies to therapeutic radioisotopes for selective tumor cell eradication. These efforts are supported by in‐house radiochemistry capabilities and collaborative research partnerships with academic institutions.

Headquartered in the United States, MAIA Biotechnology serves both domestic and international research markets and is preparing key assets for regulatory submission and first‐in‐human trials. The management team comprises industry veterans in radiopharmaceutical development and antibody engineering, and the company continues to expand its platform technology to address unmet needs in cancer diagnosis and treatment.

Key Stats

• Today's Range: $1.56 to $1.60
• 50-Day Range: $1.48 to $2.01
• 52-Week Range: $1.40 to $3.74
• Volume: 114,041 shs
• Average Volume: 369,442 shs
• Market Capitalization: $52.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MAIA Biotechnology Stock Analysis - MarketRank™

MAIA Biotechnology scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for MAIA Biotechnology.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MAIA Biotechnology are expected to decrease in the coming year, from ($1.30) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MAIA Biotechnology is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MAIA Biotechnology is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MAIA Biotechnology has a P/B Ratio of 11.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.62% of the float of MAIA Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

MAIA Biotechnology has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MAIA Biotechnology has recently decreased by 12.13%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MAIA Biotechnology does not currently pay a dividend.

Dividend Growth

MAIA Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.62% of the float of MAIA Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

MAIA Biotechnology has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MAIA Biotechnology has recently decreased by 12.13%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for MAIA Biotechnology this week, compared to 1 article on an average week.

Search Interest

23 people have searched for MAIA on MarketBeat in the last 30 days. This is an increase of 475% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added MAIA Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MAIA Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.32% of the stock of MAIA Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 5.65% of the stock of MAIA Biotechnology is held by institutions.

MAIA Stock Analysis - Frequently Asked Questions

How have MAIA shares performed this year?

MAIA Biotechnology's stock was trading at $2.09 at the beginning of the year. Since then, MAIA stock has decreased by 23.9% and is now trading at $1.59.

How were MAIA Biotechnology's earnings last quarter?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.21.

Who are MAIA Biotechnology's major shareholders?

MAIA Biotechnology's top institutional investors include Centric Wealth Management (1.89%), Geode Capital Management LLC (0.73%), Jane Street Group LLC (0.09%) and Marshall Wace LLP (0.05%). Insiders that own company stock include Stan Smith, Ngar Yee Louie, Vlad Vitoc, Cristian Luput, Ramiro Guerrero and Joseph F Mcguire.
View institutional ownership trends.

How do I buy shares of MAIA Biotechnology?

Shares of MAIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MAIA Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MAIA Biotechnology investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and AppLovin (APP).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 9/10/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:MAIA
• CIK: 1878313
• Web: www.MAIABiotech.com
• Phone: 312-416-8592
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.25 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -497.29%
• Return on Assets: -165.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.19
• Quick Ratio: 2.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.14 per share
• Price / Book: 11.36

Miscellaneous

• Outstanding Shares: 32,990,000
• Free Float: 22,330,000
• Market Cap: $52.45 million
• Optionable: Not Optionable
• Beta: 0.01